Neuphoria Therapeutics Inc

Neuphoria Therapeutics Inc. (NASDAQ: NEUP) is a clinical-stage biotechnology company. The Company is focused on developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as needed treatment of social anxiety disorder (SAD) and for chronic treatment of post-traumatic stress disorder (PTSD).

Recent Business and Financial Updates

• Neuphoria Completes Re-domiciliation and Successor Listing:
  • Neuphoria Therapeutics Inc. (Nasdaq: NEUP) has successfully implemented its previously announced re-domiciliation plan to transition Bionomics Limited’s operations from Australia to the United States. Effective December 23, 2024, New York time (December 24, 2024, Sydney time), Neuphoria has become the parent company of Bionomics. Shares of Neuphoria common stock, issued in connection with the re-domiciliation, are expected to commence trading on Nasdaq under the symbol "NEUP" starting December 24, 2024, or shortly thereafter.
  • Additionally, Neuphoria will issue options and warrants to replace existing Bionomics options and warrants. Holders of Bionomics options will receive Neuphoria options, and an institutional investor holding Bionomics warrants will receive a warrant to purchase 1,054,381 shares of Neuphoria common stock. This marks a pivotal step in aligning the companies’ operations under a unified entity.
• Publication of Positive Phase 2 Study Results for BNC210:
  • Bionomics Limited (Nasdaq: BNOX) announced the publication of favorable Phase 2 ATTUNE study results for BNC210, a treatment for post-traumatic stress disorder (PTSD), in NEJM Evidence. The data, also presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology, demonstrated significant improvements in PTSD symptom severity as early as Week 4, with sustained efficacy at Week 12. BNC210, which is non-psychedelic, non-sedating, and non-habit-forming, continues to show potential as a first-in-class treatment for PTSD.
  • Key results included statistically significant improvements in PTSD symptoms measured by the CAPS-5 scale and enhancements in depressive symptoms, sleep quality, and overall tolerability. Following a successful End-of-Phase 2 meeting with the FDA, Bionomics plans to initiate a Phase 3 study in PTSD during the second half of 2025. Concurrently, BNC210 is under evaluation in a Phase 3 AFIRM-1 study for social anxiety disorder, with results expected in Q3 2025. These advancements underscore the therapeutic promise of BNC210 for addressing high unmet needs in CNS disorders.
    

Technical Observation (on the daily chart):

The Relative Strength Index (RSI) over a 14-day period stands at a value of 49.29, currently recovered from overbought zone, with expectations of a consolidation or an upward momentum from the near important support zone of USD 3.20-USD 3.50. Additionally, the stock's current positioning is between both the 50-period SMA and 200-period SMA, which may serve as dynamic short to medium-term support and resistance levels respectively.  

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Watch’ rating has been given for Neuphoria Therapeutics Inc. (NASDAQ: NEUP) at the closing market price of USD 3.64 as of December 30, 2024. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is December 30, 2024. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.